AFS

- 14

- 055

- E January 2 3 , 2014

Exemption No. 10690C Regulatory Docket No. FAA

- 2013

- 0034

Ms. Stacy Bechdolt, Esq. Director, Safety and Technical Affairs Regional Airline Association

2025 M St reet NW, Suite 800 Washington, DC 20036

Mr. Robert Ireland Managing Director, Engineering and Maintenance

Airlines for America 1301 Pennsylvania Avenue NW, Suite 1100 Washington, DC 20004

Mr. George Paul

Director of Technical Services

National Air Carri er Association 1000 Wilson Boulevard, Suite 1700 Arlington, VA 22209

Dear Ms. Bechdolt :

This letter is to inform you that we have g ranted your petition to extend and amend Exemption No. 10690, as amended . It explains the basis for our decision , describ es its effect, and lists

the revised conditions and limitations.

The Basis for Our Decision

By letter dated November 25, 2013, you petitioned the Federal Aviation Administration (FAA) on behalf of Regional Airline Association (RAA), Airlines for America ( A4A) , and

National Air Carrier Association (NACA) for an extension and amendment to Exemption

No. 10690, as amended. Specifically, the petitioners requested the following:2

1. Extension of Exemption 10690 pertaining to Atropine, that expires on January 31, 2 014.

2. The extension should allow kits to remain in the field that are short of the substances until normally returned for refurbishment (“grandfathering”), regardless of recovery of market supplies. The intent is to continue extensions for some period aft er supplies

are restored to avoid a sudden need to refurbish kits off

- schedule, unreasonably straining supply capabilities.

3. Carriers may use their own effective means to communicate that kits already in the field are covered by the proposed extension desp ite the expiration date of January 2014 that may be apparent.

4. The extension should stipulate that it must be readily apparent that kits not containing Atropine are in compliance with Extension 10690 “as revised or extended”, without displaying the expira tion date.

5. Deletion of the requirement to carry a copy of the Exemption on board the affected

aircraft.

Your current exemption from § 121.803(c)(3) and Appendix A of Title 14, Code of Federal Regulations (14 CFR) allows RAA, A4A, and NACA relief from th e requirement to include Atropine in an Emergency Medical Kit (EMK). A condition of that exemption includes a requirement to carry a copy of the exemption aboard the affected aircraft.

In your petition, you indicate that there has been no change in the conditions and reasons relative to public interest and safety that were the basis for granting the original exemption.

The FAA has determined that good cause exists for not publishing a summary of the petition

in the Federal Register because the requeste d extension and amendment to the exemption would not set a precedent, and any delay in acting on this petition would be detrimental to RAA, A4A, and NACA.

Our Decision

The FAA has determined that the justification for the issuance of Exemption No. 10690, as amended, remains valid with respect to the this exemption and is in the public interest. Therefore, under the authority provided by 49 U.S.C. §§ 106(f), 40113, and 44701, which the FAA Administrator has delegated to me, passenger member airlines of Reg ional Airline Association, Airlines for America, and National Air Carrier Association , and all similarly situated air carriers, are granted an extension of its exemption from 14 CFR § 121.803(c) (3) and Appendix A of part 121, to the extent necessary to rel ieve them from the requirement to carry two single dose ampules of Atropine 5cc injectable, in required on

- board EMKs when, due to the nationwide shortage discussed herein, they are unable to procure these items for the3

kits . With regards to the request t o amend the Conditions and Limitations, the FAA denies the petitioners request to waive the requirements to maintain a copy of the most current exemption with the expiration date on board the affected aircraft, as it is not in the public

interest. This ex emption is subject to the following conditions and limitations.

Conditions and Limitations

1. This exemption applies to the part 119 certificate holders authorized to conduct part 121 passenger carrying operations

.

2. A copy of this exemption must be carried on board each aircraft operating with emergency medical kits that do not include Atropine as required by Appendix A of part 121.

3. As part of the requirement under §119.43(c) to keep each of its employees and other persons used in its operation informed of the provisions of their operations specifications that apply to that employee’s or person’s duties and responsibilities, the certificate holders must inform crewmembers that any emergency medical kits on board the aircraft may not contain Atropine.

4. This e xemption may be used for flights conducted outside of the United States

.

The Effect of Our Decision

Our decision extends the termination date of Exemption No. 10690, as amended, to January 31, 2015 unless sooner superseded or rescinded.

Sincerely,

/s/ John Barbagallo Acting Deputy Director, Flight Standards Service